Entries by Hanna Frykman

View Live: SenzaGen’s CEO at Financial Meetings Øresund

Live presentations at Financial Meetings Øresund’s event “Sverige fortsatt starkt för Life Science?” SenzaGen’s CEO Anki Malmborg Hager will share the inspiring story of SenzaGen and how SenzaGen’s platform GARD®, a group of tests for animal-free safety testing, can replace animal tests using genomics in test tubes to assess whether chemicals are allergenic or not. Watch live […]

SenzaGen’s CEO to speak at Financial Meetings Øresund, in Lund November 19, 2018

SenzaGen’s CEO Anki Malmborg Hager will speak at Financial Meetings Øresund, November 19, 2018. As a speakers in the event “Sverige fortsatt starkt för Life Science? Anki will share the inspiring story of SenzaGen and how SenzaGen’s platform GARD®, a group of tests for animal-free safety testing, can replace animal tests using genomics in test tubes to assess […]

SenzaGen hosts open webinars on Respiratory Sensitization on 4 and 5 December

In vitro testing for Respiratory Sensitizers using a genomic biomarker signature and the GARD™ technology platform The presentations on 4 and 5 December 2018, will give insight into the latest in vitro technology for identifying respiratory sensitizers using human dendritic-like cell lines and genomics.  A thorough explanation of the GARD™ platform will be covered as well […]

GARDair – A novel assay for assessment of chemical respiratory sensitizers based on a genomic platform

Henrik Johansson, Andy Forreryd, Robin Gradin, Angelica Johansson, Olivia Larne, Emil Aaltonen, Anders Jerre, Carl A.K. Borrebaeck and Malin Lindstedt SenzaGen AB, Lund, Sweden. Department of Immunotechnology, Lund, Sweden. Introduction Exposure to chemicals may induce allergic hypersensitivity reactions in skin or respiratory tract. To minimize exposure, chemicals are routinely screened for their sensitizing potential. Proactive […]

SenzaGen hosts network meeting Understanding Biocompatibility of Medical Devices, October 2, at Medicon Village in Lund

SenzaGen is proud to be hosting the event Understanding Biocompatibility of Medical Devices on October 2, in Lund, in cooperation with the Medicon Valley Medtech Network. The regulatory framework of the medical device industry is going through major changes and the complexity of the process is increasing due to new requirements and standards. All medical devices […]

Extended applicability domain with new solvent selection for the GARD platform

Jenvert RM, Larne O, TorstensdotterMattssonU. I., Johansson H, SenzaGen, Lund, Sweden Introduction The Genomic Allergen Rapid Detection (GARD) assay is a state of the art in vitro assay developed for the assessment of skin sensitizers. It is based on gene expression analysis of SenzaCells, a human myeloid cell line, after stimulation by the test item. During […]

Exploration of the GARD® applicability domain – Sensitization assessment of UVCBs

U. I. Torstensdotter Mattson, C. Humfrey, O. Larne, H. Johansson, L. Sweet SenzaGen, Lund, Sweden, Lubrizol, Derbyshire, United Kingdom, Lubrizol, Ohio, United States of America Introduction The GARD – Genomic Allergen Rapid Detection – platform is a state of the art in vitro assay for assessment of chemical sensitizers. The GARD®skin assay is a powerful […]

The Validation of GARD®skin

Sandberg P, Johansson A, Agemark M, Gradin R, Larne O, Appelgren H, Forreryd A, Jerre A, Edwards A, Hoepflinger V, Burleson F, Gehrke H, Roggen E, Johansson H SenzaGen, Lund, Sweden, Burleson Research Technologies, Morrisville, US, Eurofins, Munich, Germany Introduction The prevalence of allergic contact dermatitis (ACD) is estimated to >20% in the western world. […]

Predicting skin sensitizaers with confidence-Using conformal prediction to determine applicability domain

Objective GARD – Genomic Allergen Rapid Detection – is a state of the art non-animal based technology platform for classification of skin sensitizing chemicals. The assay has proven to be reliable and highly accurate for identification of skin sensitizing chemicals, and consistently reports predictive performances > 90% across external test sets. The aim of the […]

The use of GARDskin for sensitization evaluation of cosmetic ingredients and ‘real-life’ mixtures

Renato Ivan de Ávila, Tim Lindbergh, Malin Lindstedt and Marize Campos Valadares Lab. of Education and Research in Pharmacology and Cellular Toxicology, Faculty of Pharmacy, Federal University of Goiás, Goiânia, Goiás, Brazil. Department of Immunotechnology, Medicon Village, Lund University, Lund, Sweden.   Introduction Genomic fingerprints in dendritic cells after chemical exposure is a recent strategy […]